Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 91,265,480
  • Shares Outstanding, K 1,245,775
  • Annual Sales, $ 27,116 M
  • Annual Income, $ 5,665 M
  • 60-Month Beta 0.18
  • Price/Sales 3.39
  • Price/Cash Flow 8.30
  • Price/Book 4.06
Trade GILD with:

Options Overview Details

View History
  • Implied Volatility 20.75% ( -1.07%)
  • Historical Volatility 20.64%
  • IV Percentile 29%
  • IV Rank 32.29%
  • IV High 29.79% on 10/27/23
  • IV Low 16.44% on 12/05/23
  • Put/Call Vol Ratio 0.76
  • Today's Volume 6,571
  • Volume Avg (30-Day) 10,707
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 206,229
  • Open Int (30-Day) 234,702

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 1.56
  • Number of Estimates 12
  • High Estimate 1.80
  • Low Estimate 1.32
  • Prior Year 1.37
  • Growth Rate Est. (year over year) +13.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.45 +2.53%
on 02/20/24
76.21 -3.87%
on 03/11/24
+1.68 (+2.35%)
since 02/16/24
3-Month
71.37 +2.65%
on 02/16/24
87.86 -16.62%
on 01/19/24
-6.24 (-7.85%)
since 12/18/23
52-Week
71.37 +2.65%
on 02/16/24
87.86 -16.62%
on 01/19/24
-4.05 (-5.24%)
since 03/17/23

Most Recent Stories

More News
3 Cheap Dividend Stocks to Scoop Up This March

After a second straight losing week for stocks, investors in search of relative safety in the market might want to consider value-priced dividend stocks - like the three income picks we've highlighted...

KO : 60.13 (+0.42%)
DD : 73.52 (+0.12%)
BKR : 32.39 (+0.22%)
MRK : 121.44 (-0.07%)
$SPX : 5,149.42 (+0.63%)
GILD : 73.26 (-0.58%)
OC : 157.67 (-1.33%)
DOOR : 130.67 (-0.02%)
KOF : 98.28 (-0.05%)
2 Top Dividend Stocks to Buy Hand Over Fist

Every company faces headwinds eventually. The top ones know how to bounce back.

AGN.AX : 0.565 (unch)
ABBV : 178.49 (+0.34%)
GILD : 73.26 (-0.58%)
3 Dividend Stocks to Buy Hand Over Fist in March

Income investors might want to load up on these great dividend stocks.

GILD : 73.26 (-0.58%)
NVS : 95.92 (-1.39%)
PFE : 27.72 (-0.79%)
The AI Race Gets Litigious

We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.

AXON : 308.45 (+0.26%)
AAPL : 173.72 (+0.64%)
GILD : 73.26 (-0.58%)
AMGN : 270.90 (+0.76%)
EBAY : 51.35 (-1.63%)
PANW : 285.24 (+1.09%)
OKTA : 105.88 (-0.21%)
CRM : 300.51 (+2.10%)
ABBV : 178.49 (+0.34%)
3 Dividend Stocks That Are No-Brainer Buys Right Now

These stocks check off multiple boxes for investors.

ABBV : 178.49 (+0.34%)
LLY : 762.66 (+1.13%)
GILD : 73.26 (-0.58%)
History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20%

This biotech stock could be poised for a nice rebound if analysts are right.

COMP : 3.06 (+4.44%)
GILD : 73.26 (-0.58%)
Jerry Pinkas Real Estate Experts Extends a Helping Hand to Homebuyers in Myrtle Beach

Myrtle Beach, SC () February 22, 2024 -- Jerry Pinkas Real Estate Experts, located in Myrtle Beach, SC, offers expert guidance for homebuyers in the Grand Strand area, specializing in personalized service...

GILD : 73.26 (-0.58%)
S&P Posts Record High as Nvidia Pushes Tech Stocks Higher

The S&P 500 Index ($SPX ) (SPY ) today is currently up +1.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.68%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.21%. Stock indexes are sharply...

$SPX : 5,149.42 (+0.63%)
SPY : 512.86 (+0.59%)
$DOWI : 38,790.43 (+0.20%)
DIA : 387.73 (+0.19%)
$IUXX : 17,985.01 (+0.99%)
QQQ : 437.48 (+0.82%)
ZNM24 : 109-315 (+0.16%)
NVDA : 884.55 (+0.70%)
AMD : 190.65 (-0.21%)
MRVL : 67.20 (+0.49%)
AMAT : 200.73 (+1.05%)
AVGO : 1,237.24 (+0.14%)
Stocks Rally on Nvidia’s Blowout Earnings

The S&P 500 Index ($SPX ) (SPY ) today is currently up +1.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.25%. Stock indexes this morning...

$SPX : 5,149.42 (+0.63%)
SPY : 512.86 (+0.59%)
$DOWI : 38,790.43 (+0.20%)
DIA : 387.73 (+0.19%)
$IUXX : 17,985.01 (+0.99%)
QQQ : 437.48 (+0.82%)
ZNM24 : 109-315 (+0.16%)
NVDA : 884.55 (+0.70%)
AMD : 190.65 (-0.21%)
MRVL : 67.20 (+0.49%)
AMAT : 200.73 (+1.05%)
AVGO : 1,237.24 (+0.14%)
Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications

/CNW/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies today announced a new clinical collaboration...

GILD : 73.26 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 74.85
2nd Resistance Point 74.51
1st Resistance Point 73.89
Last Price 73.26
1st Support Level 72.92
2nd Support Level 72.58
3rd Support Level 71.96

See More

52-Week High 87.86
Fibonacci 61.8% 81.56
Fibonacci 50% 79.62
Fibonacci 38.2% 77.67
Last Price 73.26
52-Week Low 71.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar